Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Ubiome Gut EXPLORER : 10% OFF
Join/Watch the weekly
TMAU UP Podcasts

Videos : TMAU stories

MEBO Map Testing & Meetups

Full details :
want listed ? contact
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

£ 943.03/GBP
$ 568.00/USD

TOTAL at today's ROE
£0.80/GBP = $1.00/USD

£1,398.07 = $1,745.14



Your currency will be automatically converted to USD or GBP by PayPal.

Option: pay with your credit card instead of PayPal account by clicking on either Donate button above.

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

Wednesday, April 1, 2009

hypothesis: genetically modified probiotic for trimethylaminuria

As mentioned in an earlier post, it seems probably already technically and probably financially very feasible to develop a probiotic enriched with FMO3 enzyme that could colonise the colon and neutralize trimethylamine on-site in the gut. It has been mentioned before, as a hypothetical treatment for TMAU:

As to the future, one may envisage some new approach to treating or managing the condition quite apart form the obvious one of gene therapy with replacement of the human gene for FMO3. Alternative approaches might embrace the following: use of gut absorbents, such as charcoal or ion-exchange resins; modify the gut flora to reduce the bacterial species responsible for the conversion of precursors to trimethylamine; incorporate micro-organisms "engineered" with human FMO3 into the gut flora, to oxidize any trimethylamine released to its non-odorous N-oxide; provide riboflavin supplements, a precursor of the FAD cofactor for flavin monooxygenase function, in an attempt to maximize any residual activity; and finally, from the cosmetic point of view, the development of "malodor suppressants" in hygiene products to disguise the offensive smell of trimethylamine.

Mitchell/Smith TMAU paper 2003
Probably the main reason it hasn't been acted upon is a perceived lack of a need and profit (from the hypothetical manufacturers point of view), of which neither are likely correct. Smell problems associated with FMO3 function are likely very underestimated (the opening paper for the 2002 TMAU workshop estimated maybe 1% could be 'at risk' of TMAU). While gene-therapy is in it's infancy and may have unforeseen downsides, genetically-engineered-bacteria therapy would not have the same possible systemic downsides, since it's the bacteria that has been altered instead. however there could be unknown side-effects (for instance, would it effect the gut flora composition compared to normal people ? The gut flora is likely a powerful metabolic factor, as mentioned by Dr Manning in his interview).

Scientists are currently researching the same principle (genetically engineered bacteria for the gut) for HIV. Presumably the bacteria in this case are stopping the virus from getting to the absorption surface. In the case of TMAU, it would only need to be present in the gut too, so as to neutralize trimethylamine, although it would in theory detoxify all FMO3 substrates present in the gut (such as other sulfides, amines, phosphorus compounds etc).

The HIV research seems to have begun around 2005.
Scientists have genetically modified bacteria living in the human body to produce chemicals that block HIV infection. Although the research is still at an early stage, they hope it could eventually lead to a practical and cost effective new way to combat the virus.
There also seems to have been research with this concept in relation to other gut disorders such as Crohn's disease. There has been no feedback in our initial enquiries regarding this concept.

Note: this would not affect systemic FMO3 function other than reducing the amount of FMO3 substrates absorbed from the gut. It would be no good for internal FMO3 substrates detoxification (endogenous substrates), of which there are many. Normally most FMO3 substrates can be detoxified other slower routes. For systemic FMO3 function, either gene therapy would be a hypothetical answer, although there has been speculation that if a FMO3-bacteria could be absorbed (for instance through a nasal spray) it may produce enough FMO3 to circulate in the bloodstream and have a noticeable effect.

related links:


Post a Comment